Manufacturing, Drug Products

Avid and Argonaut Enter into Manufacturing Solutions Co-Marketing Agreement

July 30, 2020

The companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies.

Ajinomoto Bio-Pharma Services Introduces Fast-Track Drug Product Manufacturing Platform

June 30, 2020

Aji Bio-Pharma launched Ajility, a flexible platform for manufacturing vaccines and therapies.

The US Government Moves Forward with Plans for Accelerating Manufacturing of COVID-19 Vaccines and Treatments

May 18, 2020

Leadership was announced for the US government’s Operation Warp Speed program, which aims to deliver COVID-19 vaccines, therapeutics, and diagnostics.

WuXi Biologics Subsidiary in $3-Billion Vaccine Manufacturing Contract

February 18, 2020

WuXi Vaccines, WuXi Biologics’ joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with a global vaccine leader for $3 billion.

Sartorius and German Research Center Collaborate on Artificial Intelligence

December 19, 2019

Sartorius and the German Research Center for Artificial Intelligence have established a research laboratory for AI in the biopharmaceutical industry.

PCI Pharma Services Announces UK Facility Expansion

December 17, 2019

The expansion plans to build upon the company’s high potent drug manufacturing and development capabilities, including both clinical and commercial supply.

PCI Expands Illinois Pharmaceutical Manufacturing Facility

December 06, 2019

The expansion will enhance the company’s specialty drug product capabilities.

Glass Syringe System Reduces Injection Force Without Silicone

November 21, 2019

Schott and W.L. Gore introduced a prefillable, silicone-free glass syringe system, which won an award at CPhI Worldwide.

FDA Approves New Drug to Prevent HIV Infection

October 04, 2019

The agency has approved Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) for reducing the risk of HIV-1 infection.

Pii to Manufacture FDA-Approved Breast Cancer Drug

September 23, 2019

Pii is now responsible for commercial drug product production of fulvestrant, a breast cancer drug, while Sagent Pharmaceuticals, its abbreviated new drug application holder, will sell, market, and distribute the drug product in the United States.